| abstract |
Disclosed is a method for treating cancer in a patient in need of such treatment, comprising the intrathecal administration of temozolomide in a therapeutically effective amount of a pharmaceutical formulation. Here, temozolomide is a pharmaceutical formulation containing, in addition to temozolomide, at least one water-soluble diluent and at least one dissolution enhancer sufficient to substantially dissolve temozolomide or a pharmaceutically acceptable salt thereof. Wherein the dissolution enhancer is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or a combination of two or more of the above. |